flanvotumab
mAbexperimental
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01137006)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factorINHIBITOR
HGF inhibitor
TYRP1 other
Tumor-specific T-cell response via antibody-dependent cell-mediated phagocytosis (ADCP)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFlanvotumab ↗
- ChEMBLCHEMBL2108734 ↗
Also known as
- 20d7s
- flanvotumab
- imc-20d7s
- imc-20d7s
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01137006 | Phase 1 | Jun 1, 2010 | Imclone |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imclone | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1